Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Keeler, Allison M.Zieger, Marina
Semple, Carson
Pucci, Logan
Veinbachs, Alessandra
Brown, Robert H. Jr.
Mueller, Christian
Elmallah, Mai K.
Document Type
Journal ArticlePublication Date
2019-12-24Keywords
Amyotrophic lateral sclerosisALS
gene therapy
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Genetics and Genomics
Nervous System Diseases
Neuroscience and Neurobiology
Respiratory Tract Diseases
Metadata
Show full item recordAbstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that results in death from respiratory failure. No cure exists for this devastating disease, but therapy that directly targets the respiratory system has the potential to prolong survival and improve quality of life in some cases of ALS. The objective of this study was to enhance breathing and prolong survival by suppressing superoxide dismutase 1 (SOD1) expression in respiratory motor neurons using adeno-associated virus (AAV) expressing an artificial microRNA targeting the SOD1 gene. AAV-miR(SOD1) was injected in the tongue and intrapleural space of SOD1(G93A) mice, and repetitive respiratory and behavioral measurements were performed until the end stage. Robust silencing of SOD1 was observed in the diaphragm and tongue as well as systemically. Silencing of SOD1 prolonged survival by approximately 50 days, and it delayed weight loss and limb weakness in treated animals compared to untreated controls. Histologically, there was preservation of the neuromuscular junctions in the diaphragm as well as the number of axons in the phrenic and hypoglossal nerves. Although SOD1 suppression improved breathing and prolonged survival, it did not ameliorate the restrictive lung phenotype. Suppression of SOD1 expression in motor neurons that underlie respiratory function prolongs survival and enhances breathing until the end stage in SOD1(G93A) ALS mice.Source
Mol Ther Methods Clin Dev. 2019 Dec 24;17:246-257. doi: 10.1016/j.omtm.2019.12.007. eCollection 2020 Jun 12. Link to article on publisher's site
DOI
10.1016/j.omtm.2019.12.007Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43707PubMed ID
31970202Related Resources
Rights
Copyright © 2019 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.omtm.2019.12.007
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).